Carfilzomib-based regimens
| Study . | Phase . | N . | Regimen . | Dose . | Prior lines . | ≥PR % . | ≥VGPR % . | PFS (m) . | OS (m) . | Median f/u (m) . | ≥G3 toxicities . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Siegel et al, 201259 | 2 | 266 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 27 mg/m2 | 5 | 23.7 | 3.7 | 15.6 | A 24%, T 29%, L 20%, P 9.4% | ||
| Vij et al, 201260 | 2 | 59 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d | 2 | 42.4 | 17 | 8.2 | NR | 11.5 | L 13.6%, A 11.9%, N 11.9%, T 15.3%, P 13.6% |
| 70 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 27 mg/m2 | 2 | 52.2 | 28.4 | NR | NR | NR | L 18.6%, A 17.1%, N 14.3%, T 11.4%, P 11.4% | ||
| Lendvai et al, 201461 | 2 | 42 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 56 mg/m2 | 5 | 51 | NR | 4.1 | 20.3 | 18.4 | L 43%, T 32%, P 18%, A 18%, N 18%, CHF 11% |
| Badros et al,62 | 2 | 22 | CFZ+Dex | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 45 or 56 mg/m2; D 20 mg on days 1, 2, 8, 9, 15, 16 and 40 mg on day 22 | 4 | 55 | 10 | NR | NR | NR | A 27.3%, T 27.3% |
| Shah et al, 201263 | 1 | 20 | CFZ+ ARRY-520 | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 27 mg/m2 ARRY-520 escalated from 0.75 mg/m2 to 1.5 mg/m2 | 4 | 35 | 5 | NR | NR | NR | P 30%, FN 5%, sepsis 5% |
| Kaufman et al, 201358 | 1 | 10 | CFZ+ Panobinostat | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then escalation to 36 mg/m2 Panobinostat 20 mg PO 3 times per week | NR | 30 | 10 | NR | NR | NR | T 40%, N 30% |
| Vesole et al, 201464 | 1 | 21 | CRd+Vorinostat | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then escalation to 36 mg/m2; R escalation from 15 mg to 25 mg on days 1-21 PO; vorinostat escalation from 300 mg to 400 mg on days 1-7 and 15-21 q 28 d; D 40 mg/wk | 3 | 53 | NR | NR | NR | NR | N 42%, A 33%, T 42%, I 9% |
| Study . | Phase . | N . | Regimen . | Dose . | Prior lines . | ≥PR % . | ≥VGPR % . | PFS (m) . | OS (m) . | Median f/u (m) . | ≥G3 toxicities . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Siegel et al, 201259 | 2 | 266 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 27 mg/m2 | 5 | 23.7 | 3.7 | 15.6 | A 24%, T 29%, L 20%, P 9.4% | ||
| Vij et al, 201260 | 2 | 59 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d | 2 | 42.4 | 17 | 8.2 | NR | 11.5 | L 13.6%, A 11.9%, N 11.9%, T 15.3%, P 13.6% |
| 70 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 27 mg/m2 | 2 | 52.2 | 28.4 | NR | NR | NR | L 18.6%, A 17.1%, N 14.3%, T 11.4%, P 11.4% | ||
| Lendvai et al, 201461 | 2 | 42 | CFZ | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 56 mg/m2 | 5 | 51 | NR | 4.1 | 20.3 | 18.4 | L 43%, T 32%, P 18%, A 18%, N 18%, CHF 11% |
| Badros et al,62 | 2 | 22 | CFZ+Dex | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 45 or 56 mg/m2; D 20 mg on days 1, 2, 8, 9, 15, 16 and 40 mg on day 22 | 4 | 55 | 10 | NR | NR | NR | A 27.3%, T 27.3% |
| Shah et al, 201263 | 1 | 20 | CFZ+ ARRY-520 | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then 27 mg/m2 ARRY-520 escalated from 0.75 mg/m2 to 1.5 mg/m2 | 4 | 35 | 5 | NR | NR | NR | P 30%, FN 5%, sepsis 5% |
| Kaufman et al, 201358 | 1 | 10 | CFZ+ Panobinostat | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then escalation to 36 mg/m2 Panobinostat 20 mg PO 3 times per week | NR | 30 | 10 | NR | NR | NR | T 40%, N 30% |
| Vesole et al, 201464 | 1 | 21 | CRd+Vorinostat | CFZ 20 mg/m2 IV on days 1, 2, 8, 9, 15, 16 q 28 d in cycle 1, then escalation to 36 mg/m2; R escalation from 15 mg to 25 mg on days 1-21 PO; vorinostat escalation from 300 mg to 400 mg on days 1-7 and 15-21 q 28 d; D 40 mg/wk | 3 | 53 | NR | NR | NR | NR | N 42%, A 33%, T 42%, I 9% |
A, anemia; CHF, congestive heart failure; CFZ, carfilzomib; CRd, carfilzomib, lenalidomide, and dexamethasone; Dex, dexamethasone; f/u, follow-up; m, months; G, grade; IV, intravenous; L, lymphopenia; N, neutropenia; NR, not reported; OS, overall survival; P, pyrexia; PFS, progression-free survival; PO, per os; PR, partial response; q, every; T, thrombocytopenia; TTP, time to progression; VGPR, very good partial response.